Novartis (United States)

360.9k citations
8.2k papers ·

Impact in

  • Hematology top 2%
    • Chronic Myeloid Leukemia Treatments
  • Genetics top 2%
    • Chronic Lymphocytic Leukemia Research

Papers in

    • Chronic Myeloid Leukemia Treatments 370
    • Chronic Lymphocytic Leukemia Research 299
    • Hemoglobinopathies and Related Disorders 193

Novartis (United States)

7.3k papers receiving 312.5k citations

Peers

Novartis (United States)
Comparison fields: 5 of 238
  • Hematology 23.7k
  • Genetics 21.2k
  • Oncology 52.5k
  • Molecular Biology 103.8k
  • Endocrinology, Diabetes and Metabolism 23.2k
Replace GlaxoSmithKline (United States) with:
GlaxoSmithKline (United States) United States
Bristol-Myers Squibb (United States) United States
Weill Cornell Medicine United States
Sidney Kimmel Cancer Center United States
Janssen (United States) United States
North Shore University Hospital United States
The Wistar Institute United States
Merck & Co., Inc., Rahway, NJ, USA (United States) United States
Dana-Farber Brigham Cancer Center United States
Cancer Genetics (United States) United States
Novartis (United States) relative to GlaxoSmithKline (United States) United States GlaxoSmithKline (United States)'s profile →
Citations per field
00.5×2.6×
GlaxoSmithKline (United States) · 1×
Citations per year

Countries citing scholars working at Novartis (United States)

Since Specialization
Citations

This map shows the geographic impact of research produced by authors working at Novartis (United States). It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by papers produced at Novartis (United States) with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Novartis (United States) more than expected).

Fields of papers published by authors at Novartis (United States)

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers affiliated with Novartis (United States) at the time of their publication. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers affiliated with Novartis (United States) at the time of their publication.

About Novartis (United States)

In recent decades, authors affiliated with Novartis (United States) have published 8.2k papers, which have received a total of 360.9k indexed citations . Scholars at this organization have produced 803 papers in Hematology, 689 papers in Genetics, 1.1k papers in Oncology, 502 papers in Rheumatology and 667 papers in Immunology on the topics of Chronic Myeloid Leukemia Treatments (370 papers), Chronic Lymphocytic Leukemia Research (299 papers), Advanced Breast Cancer Therapies (239 papers), Spondyloarthritis Studies and Treatments (226 papers), Heart Failure Treatment and Management (218 papers), Computational Drug Discovery Methods (208 papers), Asthma and respiratory diseases (201 papers) and Hemoglobinopathies and Related Disorders (193 papers). Their work is cited by papers focused on Hematology (23.7k citations), Genetics (21.2k citations), Oncology (52.5k citations), Molecular Biology (103.8k citations) and Endocrinology, Diabetes and Metabolism (23.2k citations). Authors at Novartis (United States) collaborate with scholars in United States, Switzerland and United Kingdom and have published in prestigious journals including Blood, Journal of Clinical Oncology, Value in Health, Annals of Oncology and Annals of the Rheumatic Diseases. Some of Novartis (United States)'s most productive authors include David J. Glass, Jerry Nedelman, Peter Atadja, Derek T. O’Hagan, William R. Sellers, Scott D. Solomon, James E. Foley, Taiping Chen, John J.V. McMurray and Anja Schweizer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore institutions with similar magnitude of impact